How The Insulet (PODD) Narrative Is Shifting After Omnipod 5 Correction And Repriced Expectations

Insulet’s modeled fair value has been trimmed slightly from US$340.26 to US$326.35, indicating a more conservative price target in the updated analysis. This adjustment aligns with the mixed analyst ...
Yahoo Finance

Insulet's (PODD) Omnipod 5 Favored in Study for Type 2 Diabetes

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Seeking Alpha

Insulet to Share Additional Evidence Demonstrating the Impact of Omnipod® 5 on Improved Health Outcomes at the American Diabetes Association 85th Scientific Sessions

Presentations and panel discussions to provide deeper dives into the clinical outcomes from Insulet’s groundbreaking SECURE-T2D and RADIANT trials Real-world evidence around glycemic outcomes from ...
Healthline

Omnipod DASH vs. Omnipod 5: A Comparison

If you have type 1 diabetes, you know how difficult it can feel to manage your insulin levels and track your progress over time without turning it into something that resembles a full-time job. And ...
Business Wire

Omnipod® 5 Automated Insulin Delivery System Significantly Improves Glycemic Outcomes Over 12 Months of Use in Children Aged 2 through 5.9 Years

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented ...
DutchNews.NL

Insulet Announces CE Mark Approval of Omnipod® 5 Integration with Abbott FreeStyle Libre 2 Plus Sensor

Omnipod 5 is the world’s first tubeless automated insulin delivery system to achieve CE mark approval with multiple continuous glucose monitoring (CGM) sensor brands. Latest Omnipod 5 integration is ...